Cancer/testis antigen 1 (121-130)

Cancer/testis antigen 1 (121-130) is a synthetic peptide fragment derived from the cancer/testis antigen family, specifically spanning amino acids 121 to 130 of the parent protein. These antigens are notable for their highly restricted expression, typically limited to germ cells in the testis and aberrantly present in a variety of tumor types. The unique expression profile of cancer/testis antigens has established them as valuable molecular markers in oncology research, as well as promising targets for immunological investigations. The 121-130 sequence represents a defined epitope within this family, facilitating precise studies into peptide-mediated immune recognition, antigen processing, and peptide-protein interactions relevant to tumor biology and immunotherapy development.

Epitope mapping: The 121-130 peptide sequence serves as a well-characterized epitope for mapping T-cell and B-cell responses in the context of tumor immunology. By incorporating this peptide into assays such as ELISPOT, flow cytometry, or tetramer staining, researchers can identify and quantify antigen-specific lymphocyte populations. Such analyses are crucial for elucidating mechanisms of immune recognition and tolerance, as well as for the assessment of immunogenicity in preclinical models.

Antigen presentation studies: As a defined peptide fragment, Cancer/testis antigen 1 (121-130) is instrumental in exploring the pathways and efficiency of antigen processing and presentation by major histocompatibility complex (MHC) molecules. By loading this peptide onto antigen-presenting cells, investigators can dissect the molecular requirements for MHC class I or II presentation, analyze peptide binding affinities, and evaluate the stability of peptide-MHC complexes. These studies underpin the rational design of peptide-based vaccines and immunotherapeutic strategies.

Peptide-based immunoassays: The synthetic nature and sequence specificity of the 121-130 peptide make it an ideal reagent for the development and optimization of peptide-based immunoassays. It can be employed as a positive control or as a capture antigen in enzyme-linked immunosorbent assays (ELISA), multiplex bead assays, or other immunodetection platforms. Such applications are vital for quantifying antigen-specific antibodies or T-cell responses in experimental and translational research settings.

Peptide functionalization and conjugation: Due to its defined sequence and molecular properties, the 121-130 fragment is frequently used as a scaffold for chemical modification and conjugation studies. Researchers may attach various functional groups, fluorophores, or carrier proteins to this peptide to investigate structure-activity relationships, enhance immunogenicity, or develop targeted delivery systems. These functionalized peptides support the creation of innovative research tools and the advancement of peptide-based technologies.

Tumor antigen discovery and validation: The presence of this peptide as a representative segment of cancer/testis antigens enables its use in the screening and validation of tumor-associated antigens. By incorporating the 121-130 sequence into in vitro or ex vivo assays, scientists can assess its reactivity with patient-derived immune cells, evaluate its potential as a biomarker, and contribute to the discovery of novel targets for cancer immunotherapy. These applications are integral to the ongoing refinement of precision oncology approaches and the development of next-generation diagnostic and therapeutic modalities.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Cationic cell-penetrating peptides are potent furin inhibitors